Quarterly ResultMay 12, 2026, 05:01 PM
Eupraxia Pharmaceuticals Secures $63.2M; EP-104GI Shows Robust Data
AI Summary
Eupraxia Pharmaceuticals announced its Q1 2026 financial results, reporting a net loss of $12.7 million. The company successfully completed a $63.2 million public offering, issuing 7,607,145 common shares and 1,428,571 pre-funded warrants. This financing, combined with existing cash, provides over $140 million in cash and short-term investments, extending its runway into H2 2028. Additionally, clinical data for EP-104GI in Eosinophilic Esophagitis (EoE) from the RESOLVE trial demonstrated robust tissue health and symptom improvement after 36 weeks.
Key Highlights
- Completed $63.2 million public offering in February 2026.
- Issued 7,607,145 Common Shares at $7.00 and 1,428,571 Pre-Funded Warrants.
- Cash and cash equivalents of $58.5 million and short-term investments of $80.4 million as of March 31, 2026.
- Well-capitalized into H2 2028 with over $140 million cash.
- EP-104GI showed robust response in highest dose cohort after 36 weeks in RESOLVE trial.
- Net loss of $12.7 million for Q1 2026, compared to $6.8 million for Q1 2025.
- 61,808,630 common shares and 8,355,638 preferred shares outstanding as of March 31, 2026.